Table 1.

Essential questionnaire items

Hospital information questionnaire

Number of lung cancer/SCLC patients for primary treatment in 2005 and 2010, respectively Age, gender, stage, with or without brain metastasis at diagnosis of SCLC patients for primary treatment First-line treatment options for LS-SCLC Second-line chemotherapy regimens for patients who responded to first-line treatment and progressed Ranking of several factors including effectiveness, cost, and toxicity in regimen selection Ranking of efficacy evaluation including response rate, time to progression, progression-free survival, overall survival, quality of life

Patient information questionnaire

Gender, age, smoking history, and family history Diagnosis, stage, with or without brain metastasis First-line treatment information, including therapeutic modalities (chemotherapy alone, concurrent chemoradiotherapy or sequential chemoradiotherapy), regimen and cycles of chemotherapy, efficacy, and prophylactic cranial irradiation Second-line treatment information, including therapeutic modalities, chemotherapy regimen and cycles, efficacy Time to progression, loss of follow-up or death

LS, limited stage; SCLC, small cell lung cancer.